<DOC>
	<DOC>NCT02824224</DOC>
	<brief_summary>This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in new users of the 52mg levonorgestrel-releasing intrauterine device. Half of participants will receive a course of tamoxifen three weeks after insertion of the IUD, while the other half of participants will receive a course of placebo.</brief_summary>
	<brief_title>Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)</brief_title>
	<detailed_description>New users of the LNG IUS will be eligible. Subjects will be randomized to receive tamoxifen 10 mg BID for 7 days or placebo. Study drug will be started 3 weeks after placement of the IUS. Subjects will maintain a record of daily bleeding and spotting using an electronic text messaging diary.</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Menorrhagia</mesh_term>
	<mesh_term>Metrorrhagia</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>initiating use of 52mg levonorgestrelreleasing IUD for contraceptive purposes access to reliable cell phone willing to receive and respond to daily text or email message to assess bleeding using IUD for indication other than contraception postpartum within 6 months, pregnant, or breastfeeding removal and replacement of IUD undiagnosed abnormal uterine bleeding prior to placement of IUD bleeding dyscrasia anticoagulation use active cervicitis allergy to tamoxifen history of venous thromboembolism personal history of breast or uterine malignancy use of medication contraindicated with use of tamoxifen (coumadin, letrozole, bromocriptine, rifampicin, aminoglutethimide, phenobarbital)</criteria>
	<gender>Female</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>levonorgestrel</keyword>
	<keyword>breakthrough bleeding</keyword>
</DOC>